Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $80.00

Dianthus Therapeutics (NASDAQ:DNTH) had its price target boosted by Wedbush from $55.00 to $80.00 in a research note released on Tuesday morning,Benzinga reports. Wedbush currently has an outperform rating on the stock.

A number of other research analysts have also commented on the company. TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a research note on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Wednesday, January 21st. Jefferies Financial Group set a $98.00 price objective on shares of Dianthus Therapeutics and gave the stock a “buy” rating in a report on Monday. Robert W. Baird upped their target price on shares of Dianthus Therapeutics from $67.00 to $132.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, Stifel Nicolaus set a $120.00 price target on shares of Dianthus Therapeutics in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $115.33.

Dianthus Therapeutics Stock Performance

NASDAQ DNTH opened at $80.32 on Tuesday. Dianthus Therapeutics has a twelve month low of $13.36 and a twelve month high of $88.02. The stock has a market cap of $3.57 billion, a PE ratio of -19.59 and a beta of 1.56. The firm has a 50-day simple moving average of $51.76 and a 200 day simple moving average of $42.18.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Monday, March 9th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.46). Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%. The firm had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.40 million. Research analysts forecast that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

Several large investors have recently made changes to their positions in the company. Raymond James Financial Inc. bought a new position in Dianthus Therapeutics during the 2nd quarter valued at about $27,000. Parkside Financial Bank & Trust raised its stake in shares of Dianthus Therapeutics by 131.7% in the third quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock valued at $37,000 after acquiring an additional 540 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Dianthus Therapeutics in the 4th quarter worth approximately $40,000. Russell Investments Group Ltd. bought a new stake in Dianthus Therapeutics during the 3rd quarter worth approximately $64,000. Finally, Tower Research Capital LLC TRC increased its holdings in Dianthus Therapeutics by 330.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock valued at $80,000 after purchasing an additional 3,317 shares in the last quarter. Institutional investors own 47.53% of the company’s stock.

Key Dianthus Therapeutics News

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Multiple analyst upgrades/positive notes pushed upside sentiment — Raymond James raised to Strong-Buy, Wedbush and Robert W. Baird published bullish commentary, and Truist raised its price target to $110. Raymond James Upgrade Wedbush Note Baird Note Truist PT Increase
• Neutral Sentiment: Dianthus closed its upsized underwritten offering: 8,470,989 common shares (plus pre-funded warrants), full exercise of the underwriters’ option, at $81.00 for gross proceeds of ~ $719M — strengthens the balance sheet and funds development but increases share count (dilution). Offering Close
• Neutral Sentiment: Prior pricing announcement (pricing of the upsized $625M offering before exercise) set the $81 deal terms and underwriter option that later pushed the deal to $719M; useful for timeline context. Offering Pricing
• Neutral Sentiment: Reported short interest entries show effectively zero reported short volume and a 0.0 days-to-cover figure (data may be placeholder/insignificant) — not a meaningful driver.
• Negative Sentiment: HC Wainwright sharply lowered near‑term and multi‑year EPS forecasts (Q1–Q4 2026 and FY2026–FY2028 trimmed substantially) while keeping a Buy and $130 target — the cuts signal updated modeling for higher costs or slower commercialization timelines and may weigh on near‑term sentiment. HC Wainwright Note (MarketBeat)

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.